Divergent cardiac effects of the first and second generation hypoglycemic sulfonylurea compounds.

Article Details

Citation
Copy to clipboard

Ballagi-Pordany G, Koszeghy A, Koltai MZ, Aranyi Z, Pogatsa G

Divergent cardiac effects of the first and second generation hypoglycemic sulfonylurea compounds.

Diabetes Res Clin Pract. 1990 Jan;8(2):109-14.

PubMed ID
2106423 [ View in PubMed
]
Abstract

The effects of first and second generation hypoglycemic sulfonylureas on the incidence of ventricular ectopic beats and on the duration of transitional ventricular fibrillation in the ischemic rat heart were investigated. First generation sulfonylurea compounds (tolbutamide, carbutamide and gliclazide) in 105 preparations increased, while second generation sulfonylurea compounds (glibenclamide and glipizide) in 50 preparations decreased in a dose-dependent manner both the number of ventricular ectopic beats and the duration of transitional ventricular fibrillation during the first 30 min after ligation of the left anterior descending coronary artery. Therefore, second generation sulfonylureas should be preferred in the treatment of type 2 diabetics with ischemic heart diseases, if satisfactory metabolic control cannot be achieved by a treatment regimen and diet alone.

DrugBank Data that Cites this Article

Drugs